aristolochic acid D has been researched along with aristolochic acid i in 4 studies
*aristolochic acid I: phospholipase A inhibitor [MeSH]
*aristolochic acid I: phospholipase A inhibitor [MeSH]
| Studies (aristolochic acid D) | Trials (aristolochic acid D) | Recent Studies (post-2010) (aristolochic acid D) | Studies (aristolochic acid i) | Trials (aristolochic acid i) | Recent Studies (post-2010) (aristolochic acid i) |
|---|---|---|---|---|---|
| 10 | 0 | 4 | 1,088 | 2 | 548 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borges, S; Chan, TM; Fischmann, T; Gullo, VP; Hegde, VR; Kirschmeier, P; Madison, V; Patel, M; Pu, H; Williams, MJ; Wu, B | 1 |
| Chang, FR; Chen, LC; Chuang, LY; Chung, YM; Hwang, TL; Lee, CL; Lin, ZY; Su, JH; Tseng, TF; Wu, SF; Wu, YC | 1 |
| Han, J; Li, C; Liang, A; Liu, S; Meng, J; Pan, C; Tian, J; Wang, D; Wang, F; Wang, L; Xian, Z; Yi, Y; Zhang, Y; Zhao, Y | 1 |
| Han, J; Li, C; Liang, A; Liu, C; Liu, S; Meng, J; Pan, C; Tang, X; Tian, J; Wang, D; Wang, F; Wang, L; Wang, Y; Xian, Z; Yi, Y; Zhang, Y; Zhao, Y | 1 |
4 other study(ies) available for aristolochic acid D and aristolochic acid i
| Article | Year |
|---|---|
Semi-synthetic aristolactams--inhibitors of CDK2 enzyme.
Topics: Aristolochic Acids; CDC2 Protein Kinase; Cell Line, Tumor; Computer Simulation; Crystallography, X-Ray; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Structure; Pyrazoles; Quinolines; Structure-Activity Relationship | 2010 |
A novel alkaloid, aristopyridinone A and anti-inflammatory phenanthrenes isolated from Aristolochia manshuriensis.
Topics: Anti-Inflammatory Agents; Aristolochia; Biphenyl Compounds; Cell Line, Tumor; Ethers; Humans; Inhibitory Concentration 50; Leukocyte Elastase; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Quinolines | 2011 |
Study on the potential nephrotoxicity and mutagenicity of aristolochic acid IVa and its mechanism.
Topics: Animals; Aristolochic Acids; Carcinogens; Dose-Response Relationship, Drug; Female; Kidney Diseases; Male; Mice; Mice, Inbred C57BL; Mutagens; Time Factors | 2021 |
Differences in p38-STAT3-S100A11 signaling after the administration of aristolochic acid I and IVa may account for the disparity in their nephrotoxicity.
Topics: Animals; Aristolochic Acids; Fibrosis; Kidney; Kidney Diseases; Mice; Proteomics; S100 Proteins; Signal Transduction | 2023 |